HKD 1.32
(0.0%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -376.56 Million CNY | 6.83% |
2022 | -404.17 Million CNY | -10.94% |
2021 | -364.33 Million CNY | 49.77% |
2020 | -725.32 Million CNY | -501.96% |
2019 | -120.49 Million CNY | -235.26% |
2018 | -35.94 Million CNY | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -53.32 Million CNY | 0.0% |
2024 Q1 | -53.32 Million CNY | 71.68% |
2023 Q3 | -96.43 Million CNY | 26.06% |
2023 FY | -376.56 Million CNY | 6.83% |
2023 Q4 | -188.28 Million CNY | -95.24% |
2023 Q2 | -130.41 Million CNY | 0.0% |
2023 Q1 | -130.41 Million CNY | -1.0% |
2022 Q3 | -129.12 Million CNY | -67.59% |
2022 Q2 | -77.04 Million CNY | 0.0% |
2022 Q1 | -77.04 Million CNY | 8.42% |
2022 FY | -404.17 Million CNY | -10.94% |
2022 Q4 | -129.12 Million CNY | 0.0% |
2021 Q1 | -115.3 Million CNY | -111.15% |
2021 Q2 | -115.3 Million CNY | 0.0% |
2021 Q4 | -84.12 Million CNY | 0.0% |
2021 Q3 | -84.12 Million CNY | 27.04% |
2021 FY | -364.33 Million CNY | 49.77% |
2020 Q4 | -54.6 Million CNY | 0.0% |
2020 Q1 | -21.77 Million CNY | -2.28% |
2020 Q2 | -21.77 Million CNY | 0.0% |
2020 FY | -725.32 Million CNY | -501.96% |
2019 FY | -120.49 Million CNY | -235.26% |
2019 Q4 | -21.29 Million CNY | 0.0% |
2018 FY | -35.94 Million CNY | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Uni-Bio Science Group Limited | 67.76 Million HKD | 655.671% |
CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 141.936% |